Jc. Garciapagan et J. Bosch, PHARMACOLOGICAL PREVENTION OF VARICEAL BLEEDING - NEW DEVELOPMENTS, Bailliere's clinical gastroenterology, 11(2), 1997, pp. 271-287
The introduction of pharmacological therapy has been one of the major
advances in the treatment of the complications of portal hypertension.
Many drugs have been shown to reduce portal hypertension in patients
with cirrhosis. However, the most widely used drugs and the only ones
for which there is sufficient evidence, are the beta-blockers. These d
rugs have been, up to now, the only accepted prophylactic therapy for
oesophageal variceal bleeding and are also an alternative treatment to
sclerotherapy or surgery to prevent variceal rebleeding. A reduction
in portal pressure gradient by beta-blockers below 12 mmHg or by more
than 20% of baseline values is associated with almost a total protecti
on from oesophageal bleeding. Such a marked response in portal pressur
e is only achieved in some patients receiving propranolol. New pharmac
ological approaches with a greater portal pressure reducing effect may
improve the beneficial effect of drugs in preventing variceal bleedin
g. The more promising approach is the combined administration of beta-
blockers and isosorbide-5-mononitrate, which has been shown to potenti
ate the reduction in portal pressure and to be highly effective in ini
tial randomized clinical trials.